270 related articles for article (PubMed ID: 22139613)
1. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab.
Wittström E; Holmberg H; Hvarfner C; Andréasson S
Eur J Ophthalmol; 2012; 22(4):563-74. PubMed ID: 22139613
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
3. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.
Tatsumi T; Yamamoto S; Uehara J; Sugawara T; Baba T; Inoue M; Hata H; Mitamura Y
Graefes Arch Clin Exp Ophthalmol; 2013 May; 251(5):1355-60. PubMed ID: 23250484
[TBL] [Abstract][Full Text] [Related]
4. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
[TBL] [Abstract][Full Text] [Related]
5. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
Alkawas AA; Shahien EA; Hussein AM
J Glaucoma; 2010 Dec; 19(9):622-6. PubMed ID: 20179624
[TBL] [Abstract][Full Text] [Related]
6. [Results of trabeculectomy with anti-VGEF therapy in the treatment of neovascular glaucoma secondary to retinal vein occlusion (report of 21 cases followed at Bukavu Eye Clinic from January 1 to December 31th, 2015)].
Kabesha TB; Kabesha D; Maloba V; Mwamba C; Chenge B; Mukalay A
J Fr Ophtalmol; 2017 Jan; 40(1):17-21. PubMed ID: 27884546
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.
Eid TM; Radwan A; el-Manawy W; el-Hawary I
Can J Ophthalmol; 2009 Aug; 44(4):451-6. PubMed ID: 19606170
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.
Moraczewski AL; Lee RK; Palmberg PF; Rosenfeld PJ; Feuer WJ
Br J Ophthalmol; 2009 May; 93(5):589-93. PubMed ID: 19074917
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.
Olmos LC; Sayed MS; Moraczewski AL; Gedde SJ; Rosenfeld PJ; Shi W; Feuer WJ; Lee RK
Eye (Lond); 2016 Mar; 30(3):463-72. PubMed ID: 26681145
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.
Sun Y; Liang Y; Zhou P; Wu H; Hou X; Ren Z; Li X; Zhao M
BMC Ophthalmol; 2016 Aug; 16(1):150. PubMed ID: 27576739
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma.
Ciftci S; Sakalar YB; Unlu K; Keklikci U; Caca I; Dogan E
Eur J Ophthalmol; 2009; 19(6):1028-33. PubMed ID: 19882572
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for neovascular glaucoma.
Vasudev D; Blair MP; Galasso J; Kapur R; Vajaranant T
J Ocul Pharmacol Ther; 2009 Oct; 25(5):453-8. PubMed ID: 19857107
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma.
Mahdy RA; Nada WM; Fawzy KM; Alnashar HY; Almosalamy SM
J Glaucoma; 2013 Dec; 22(9):768-72. PubMed ID: 22790513
[TBL] [Abstract][Full Text] [Related]
14. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.
Yazdani S; Hendi K; Pakravan M; Mahdavi M; Yaseri M
J Glaucoma; 2009; 18(8):632-7. PubMed ID: 19826393
[TBL] [Abstract][Full Text] [Related]
16. Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab.
Fong AW; Lee GA; O'Rourke P; Thomas R
Clin Exp Ophthalmol; 2011; 39(4):318-23. PubMed ID: 20973900
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
18. [Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases].
Douat J; Auriol S; Mahieu-Durringer L; Ancèle E; Pagot-Mathis V; Mathis A
J Fr Ophtalmol; 2009 Nov; 32(9):652-63. PubMed ID: 19892433
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Iliev ME; Domig D; Wolf-Schnurrbursch U; Wolf S; Sarra GM
Am J Ophthalmol; 2006 Dec; 142(6):1054-6. PubMed ID: 17157590
[TBL] [Abstract][Full Text] [Related]
20. Role of intravitreal bevacizumab in neovascular glaucoma.
Gheith ME; Siam GA; de Barros DS; Garg SJ; Moster MR
J Ocul Pharmacol Ther; 2007 Oct; 23(5):487-91. PubMed ID: 17900231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
